


PRODUCT: SL327

ALTERNATE NAMES: SL-327; SL 327; α -[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)-benzeneacetonitrile; (Z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile

CATALOG#: B1694-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₆H₁₂F₃N₃S

MOLECULAR WEIGHT: 335.4

CAS NUMBER: 305350-87-2

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: SL-327 is a selective inhibitor of MEK1 and MEK2 with IC50 value of 0.18 and 0.22 μ M, respectively.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Scherle P A et al. Regulation of Cyclooxygenase-2 Induction in the Mouse Uterus During Decidualization AN EVENT OF EARLY PREGNANCY[J]. Journal of Biological Chemistry, 2000, 275(47): 37086-37092.
2. Radwanska K et al. Extracellular signal-regulated kinases (ERKs) modulate cocaine-induced gene expression in the mouse amygdala[J]. European Journal of Neuroscience, 2005, 22(4): 939-948.
- 3 Ramos-Miguel A et al. The time course of unconditioned morphine-induced psychomotor sensitization mirrors the phosphorylation of FADD and MEK/ERK in rat striatum: role of PEA-15 as a FADD-ERK binding partner in striatal plasticity[J]. European Neuropsychopharmacology, 2010, 20(1): 49-64.

RELATED PRODUCTS:

- Doramapimod (Cat. No. 1954-5, 25)
- PD1834352 (CI-1040) (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- Sorafenib (Cat. No. 1594-25, 100)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1, 5)

USAGE: *FOR RESEARCH USE ONLY! Not to be used in humans*